NEW YORK, NY / ACCESSWIRE / March 15, 2017 /
Long term success in the medical sector is dependent on a number of factors – innovation and demand for a particular drug; the use of a medical service, such as an urgent care clinic, by the public; or remaining price competitive within your industry. The two stocks that are highlighted have been in business for more than a decade, and are well-known brand names in the community. Investors should recognize when the writing on the wall tells them their investment does not have enough cash to fuel a recovery.

RDI Initiates
Coverage:

Adeptus Health Inc. https://ub.rdinvesting.com/news/?ticker=ADPT

Valeant Pharmaceuticals
Intl Inc. https://ub.rdinvesting.com/news/?ticker=VRX

Adeptus Health saw its stock price carved out by a third (36.21%) in Tuesday’s trading, as the price plunged to $1.48, down 84 cents per share. The company filed for a delay in reporting its 10K form to the Securities and Exchange Commission on March 2nd, giving rise to speculation that the company is in serious financial trouble as it disclosed material weaknesses with respect to internal control over financial reporting and its share price tanked by 57 percent on the same day. Investor lawsuits have followed. The recommendations from investment firms range wildly, from “buy” to “sell.” What is obvious is there is a lot of confusion in where the forward direction of the company will land it. The company reported a loss of $560 million in 2016, and has taken out a $7.5 million loan in the form of credit as it expressed substantial doubt over its ability to continue without committed long-term financing. In addition to the cash problems, Adeptus has hired a chief restructuring officer. It serves patients in Texas, Colorado, Arizona and Ohio and has about 3200 employees.

Access RDI’s Adeptus Health Research Report at: https://ub.rdinvesting.com/news/?ticker=ADPT

Valeant Pharmaceuticals International stock fell by $1.22, taking a 10 percent dive to close at $10.89 a share. The current thinking on The Street is that is headed even lower, perhaps to bankruptcy. The reason? Pershing Square’s Bill Ackman sold all of his stake (5.3 percent of the company) and took about a $3 billion loss for the decision. If you are not familiar with the brand name Valeant Pharmaceuticals, you are likely familiar with one of its cores assets- Bausch and Lomb eye care products. In fact, investors are saying the remaining divisions of Valeant are what has been driving the price of the stock down. In a decade it had spent billions to acquire companies such as Coria Laboratories for $95 million and DermaTech for $12.6 million. The end of the spending spree took place in 2015, as the company outbid its competition and acquired gastrointestinal treatment drug developer Salix Pharmaceuticals for $14.5 billion. Valeant was also in the news in 2015 for hiking prices of its drugs by several hundred to thousands percentages without any significant improvement in drug formula and invited spate of investigations. With nearly $30 billion debt pile, company drew out debt refinancing plan on March 6, which includes dropping protection on existing debt and issuing additional bonds and Valeant’s Papa also claimed last year to generate $8 billion cash by selling non-core assets. It is up to investors to decide whether it is too little too late or the company has chance to survive.

Access RDI’s Valeant Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=VRX

Our Actionable Research on Adeptus Health Inc. (NYSE: ADPT) and Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457309

NEW YORK, NY / ACCESSWIRE / March 15, 2017 /
The difference between DragonWave and Disney can be simply stated by looking at their respective stock prices. DragonWave, a company that potentially will help Disney increase their exposure, sells for $1.90 a share while Disney, who will likely be an indirect user of DragonWave products, sells for $100 more a share. Both are using new marketing channels to expand their respective businesses, and will more than likely see the expansion reflected in their bottom line.

RDI Initiates
Coverage:

DragonWave, Inc. https://ub.rdinvesting.com/news/?ticker=DRWI

Walt Disney Co. https://ub.rdinvesting.com/news/?ticker=DIS

DragonWave, Inc., a Canadian company that sells high capacity microwave packet technology to wireless communication companies, saw its shares rise 75 cents to $1.90 on Tuesday. The substantial rise in price was the results of a sales and service agreement signed with Australian company Ingram Micro announced yesterday. Packets are the basic data component that is transmitted from one telecommunication device to another. The more data you can pack in, the more data the user at the other end receives. The new deal will help DragonWave begin to realize positive profit margin, as it has accumulated $48 million in sales. DragonWave’s new partner claims it has the largest assortment of IT products and services, giving the company a pathway into a world market with a supportive partner.

Access RDI’s DragonWave Research Report at: https://ub.rdinvesting.com/news/?ticker=DRWI

Disney company shares rose 79 cents to close at $112.31 on Tuesday. A number of investment analysts are bullish on the stock, with “buy” recommendations outpacing “sell” ratings by more than a 4 to 1 ratio. The company continued with its plans to buy debt-laden Paris theme park operator Euro Disney despite resistance from European hedge fund CIAM who holds a 1.4% stock interest in Euro Disney. Walt Disney has an 85.7% stake in Euro World, and after buying it said it will delist the company once it owns 95% of the company. The fracas has had no effect on the price of Disney stock.

Access RDI’s Walt Disney Research Report at: https://ub.rdinvesting.com/news/?ticker=DIS

Our Actionable Research on DragonWave, Inc. (NASDAQ: DRWI) and Walt Disney Co. (NYSE: DIS) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457314

NEW YORK, NY / ACCESSWIRE / March 15, 2017 /
The development of a drug and receiving a passing grade from the FDA is not always enough to keep a company financially solvent. Investors are required to be willing to inject a large dose of hope into their choice of biotech stocks. According to BIO, a major trade association that represents biotech companies, “The overall likelihood of approval (LOA) from Phase I for all developmental candidates was 9.6%, and 11.9% for all indications outside of Oncology.” Basically, there is a 1 in 10 chance your investment will pay off.

RDI Initiates
Coverage:

Galectin Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=GALT

Aratana Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=PETX

A positive result from a small scale study on Galectin Therapeutics GR-MD-02 drug caused a 3.3 percent increase in the company’s stock price, up 6 cents to $1.87 a share. The GR-MD-02 drug is designed to target the galectin-3 protein which plays a critical role in the progression of fatty liver disease and fibrosis. The small bump in price is a continuation of a late January rally in the stock as investors are beginning to see the stock in a new light after its initial Phase 2 results caused to the stock to drop dramatically last November. The latest results show the drug to be safe, with one patient responding very positively to the tests. It currently has a price to book (P/B) ratio of 14.96.

Access RDI’s Galectin Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=GALT

Aratana Therapeutics reported a net loss of $23.3 million for the 4th quarter ending December 31, 2016. The loss, combined with the announcement that its revenues were $292,000, resulted in the price of its stock declining $1.32 to $5.63 a share in a couple of days. The 23+ percent drop is largely in part due to the delay of its Entyce drug for oral appetite simulation in dogs, now scheduled to be available for deliver in late 2017. Earlier in February class action lawsuit has been initiated against the company for misleading statements about Entyce regarding manufacturing contracts and timeline for a commercial launch. The company says it has $88 million in cash, sufficient to keep its operations going until the first quarter of 2018. The $292,000 revenue fell far short of Wall Street analyst expectations of $923,000. Aratana is a company that develops drugs for cats and dogs.

Access RDI’s Aratana Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=PETX

Our Actionable Research on Galectin Therapeutics Inc. (NASDAQ: GALT) Aratana Therapeutics Inc. (NASDAQ: PETX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457311

NEW YORK, NY / ACCESSWIRE / March 15, 2017 / Biotech stocks are among the most volatile sectors on the market as much of their stock price is directly connected to the success or failure of their niche drug products. Research and development costs and meeting FDA approval requirements often require the company to either have reliable investors who are willing to weather the decisions of the FDA testing cycle or have a large cash reserve when starting the company.

RDI Initiates
Coverage:

Antares Pharma Inc. https://ub.rdinvesting.com/news/?ticker=ATRS

Nivalis Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=NVLS

Antares Pharma saw its stock rise more than 4 percent, as it closed at $2.59 a share, up 10 cents. This, despite the company reporting a 3 cent per share loss in earnings for the 4th quarter. Revenue in the fourth quarter increased by 20 percent to $14.2 million from $11.8 million revenue in the same reporting period one year ago. Antares stock has been on a steady rise for the past year. The company develops and manufactures pressure-assisted injector devices that allow patients to self-inject prescription drugs. The devices have options for both needle and needleless injections. The company’s current project is the development of a single dose auto-injector for OTREXUP (methotrexate).

Access RDI’s Antares Pharma Research Report at: https://ub.rdinvesting.com/news/?ticker=ATRS

Nivalis Therapeutics ticked up 4 cents a share Tuesday, to close at $2.96 a share, up 1.34 percent. As it reported failed Phase 2 trial of its N9115 drug candidate for the treatment of cystic fibrosis, Nivalis stock fell off the shelf in November 28, 2016 when its shares fell to $2.17 a share after a $6.17 per share price the day before. The company was created to discover and develop products for patients with cystic fibrosis in the United States. Its lead product candidate is N91115, also known as cavosonstat. Nivalis hasn’t started generating any revenue and the company has reported net loss of $31.9 million and $22.9 million for year 2016 and 2015 respectively. The company has no debt on its books and a $61 million cash reserve as on December 31st, 2016. As the company is actively looking for strategic alternatives to maximize shareholders value, this makes the company a possible takeover candidate and considering the market for its lead product targets a potential population of 100,000 patients, hardly enough to sustain the company over the long term given the existing competition. Yet when taking into consideration the company’s significant drop in price from what it was just 6 months ago, there is likely more than meets the eye to this company’s present stock value and overall future.

Access RDI’s Nivalis Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=NVLS

Our Actionable Research on Antares Pharma Inc. (NASDAQ: ATRS) and Nivalis Therapeutics Inc. (NASDAQ: NVLS) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457310

NEW YORK, NY / ACCESSWIRE / March 15, 2017 /
The increased oil production by Saudi Arabia to 10 million barrels a month by reversing about a third of its production cut in February has come ashore to affect the outlooks for American oil companies like Chevron and Exxon Mobile. Oil has been surging of recent, approaching the $50 per barrel mark, having settled to $47.72 and is not expected to challenge the $50 barrier in the near term, however it gained back to the level above $48 after Saudi Arabia explained increased in production.

RDI Initiates
Coverage:

Chevron Corporation https://ub.rdinvesting.com/news/?ticker=CVX

Exxon Mobil
Corporation https://ub.rdinvesting.com/news/?ticker=XOM

Chevron was one of the companies put on investor watch lists for Tuesday. The company posted a share decline of $1.99 in stock value, closing at $107.36. After hours trading did begin to show signs of a small price recovery. Its drop was one lowlight that led the Dow Industrials decline of 44 points for the day. Despite the negative trend on oil prices, there are still a number of investment rating analysts recommending a “buy” of the stock, while a growing number downgraded their short term views to “hold”. A look in the rear view mirror to January’s earnings report has Chevron missing analysts’ expectations, as the company posted a 22 cent earnings per share for the 4th quarter on January 27th, missing predictions by 42 cents a share, according to Thomson Reuters.

Access RDI’s Chevron Corporation Research Report at: https://ub.rdinvesting.com/news/?ticker=CVX

Tuesday’s drop of Exxon Mobil stock of 44 cents a share is the result of a mixed bag of news making its way through the industry. Interestingly, it has little to do with the Saudi increase in production and more to do with the company’s financials. Its closing price of $80.99 saw an uptick in the early hours of after-hours trading. There are rumors that Exxon Mobile is interested in making a takeover bid for British Petroleum, but the contrarian view is that such a takeover would cause more problems than solutions because it is not a good strategic fit. Then there is the news of the company increasing its capital expenditures, at a time when the vast majority of major oil companies are standing pat with their own or even trimming back to improve their cash flow. The fact that Exxon Mobil can do this given the current environment says more about the company’s internal potential regardless of the external factors.

Access RDI’s Exxon Mobil Research Report at: https://ub.rdinvesting.com/news/?ticker=XOM

Our Actionable Research on Chevron Corporation (NYSE: CVX) and Exxon Mobil Corporation (NYSE: XOM) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457312

ReleaseID: 457349

BURNABY, BC / ACCESSWIRE / March 15, 2017 / Bayhorse Silver Inc. (TSXV: BHS) (the “Company” or “Bayhorse”) has commissioned the crusher/upgrader equipment at its Bayhorse Silver Mine and commenced crushing and upgrading silver bearing mineralized material (“Material”) recently extracted from the Mine.

The upgraded material will be stockpiled at the mine in 1,000 kilo (2,200 lb) supersacks, that will be individually assayed. Samples of the material and the assays will be submitted to interested potential purchasers.

The Company anticipates that up to 10,000 kilos of sacked upgraded material will be available for shipping by the end of April, 2017, with increasing quantities available as upgrading operations ramp up.

Three supersacks containing 3,000 kilos (6,600lb) of crushed mineralization will be shipped to Steinert US to refine the Ore-Sorting equipment algorithm settings to ensure maximum Ore-Sorting separation of non-mineralized from mineralized material. By removing non-mineralized material from the process stream, substantial processing cost savings can be achieved.

Cannot view this image? Visit: http://www.accesswire.com/uploads/25646_a1489526751602_85.jpg

With the crushing/upgrading plant commissioned, the Company will now focus on extracting up to 30,000 tonnes of mineralized material from the intermediate and upper workings of the Bayhorse Silver Mine for upgrading.

Bayhorse CEO Graeme O’Neill comments, “This milestone could not have been achieved without the support of its stakeholders, shareholders and the dedication and professionalism of its consultants and on-ground personnel who are committed to bringing the Bayhorse Silver Mine to an operational state.”

Historically, Silver King Mines drilled 90 underground drill holes in 1984 totaling 15,000 feet. Using a 6 oz/ton silver cut off grade, mining of 5,718 tons averaging 16.7 oz/t silver (572.5 g/t silver) was accomplished. Historic records indicate that of the 5,718 tons produced, 23% graded between 21 – 100 oz/t silver, 71% graded between 6 – 20 oz/t silver, and 6% graded less than 6 oz/t silver. On an overall basis copper averaged 1% . The highest grade sample reported from the 1984 drilling, sampling and mining program assayed 691 oz/t silver (23,691 g/t) and 15.72% copper from a mined round containing a tetrahedrite-tennantite-rich vein.

Minerals Production Yearbook (Jacobsen, 1959), reported total historic production from the Bayhorse Mine through 1959 as 286,000 ounces of silver from 8,300 tons of mineralization for an average of approximately 34.5 oz/t silver (1,183 g/t silver). Herdrick (1981) estimated remaining shipping material to be 166,208 tons at an average grade of between 17 and 20 oz/t, at a 7.5 oz/t silver cutoff, of which Silver King mined 5,718 tons at an average grade of 16.7 oz/t silver using a 6 oz/ton silver cut-off. No mining has been conducted at the Bayhorse Silver Mine since Silver King ceased its 1984 mining program.

The Company advises that this information is of a historic nature. Historic production estimates, drill information and grades reported have not been verified; A qualified person has not done sufficient work to verify the historical estimates nor classify the historical estimates as current mineral resources or mineral reserves and the Company is not treating the historical estimates as current mineral resources or mineral reserves.

The Company advises it is not basing its decision to produce on a feasibility study of mineral reserves demonstrating economic and technical viability and also advises there is increased uncertainty and specific economic and technical risks of failure associated with its production decision.

This News Release has been prepared on behalf of the Bayhorse Silver Inc. Board of Directors, which accepts full responsibility for its contents Dr. S. A. Jackson, P.Geo., a Qualified Person has prepared, supervised the preparation of, or approved the technical content of this press release.

On Behalf of the Board
Graeme O’Neill, President

Bayhorse Silver Inc., a junior exploration company, is earning an 80% interest in the historic Bayhorse Silver Mine, Oregon, USA. Bayhorse is also earning a 75% interest in the past producing Bridging the Gap Project, consisting of ASARCO’s historic Crown Point, Silver King, Ranger, Wyoming, Curlew, and Blackhawk silver/lead/zinc mines in Idaho’s Silver Valley. The Company has an experienced management and technical team with extensive exploration and mining expertise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Bayhorse Silver Inc.

ReleaseID: 457348

SYRACUSE, NY / ACCESSWIRE / March 15, 2017 / LifeSource Health, Inc.’s first product has achieved certification that the system complies with the regulatory requirements governing the transmittal of personal health information. The certification of “AtTheScene™” comes via the Drummond Group LLC, an Authorized Certification Body (ACB) empowered to test software for compliance with the requirements of the federal government.

AtTheScene is a cloud-based mobile platform that accesses a patient’s medical information that resides within the regional Health Information Exchange (HIE). The platform is designed to allow emergency medical responders (EMTs) access to patient information that may be essential to preserving life, such as patient allergies, prescribed drugs and recent medical history. The system delivers a concise report to the first responder quickly, accurately and securely, resulting in improved patient outcomes, reduced costs and saved lives. HIEs are regional and state-based organizations established to collect and maintain personal health information and to make the information available to health care providers, such as doctors, hospitals and clinics.

EMTs provide about 40 million medical transports annually throughout the country. There are over 19,000 emergency medical (ambulance) agencies in the US, all of which will be eligible to access AtTheScene via their mobile devices or laptops. LifeSource will provide certified access to medical data for all interested licensed agencies.

“The certification of our cloud-based mobile platform, AtTheScene, is a testament to our company’s focus and commitment to provide critical patient data to healthcare providers and first responders when and where they need it most,” said David LaVance, President of LifeSource Health, Inc. He further stated, “Over the past two decades health care information has been gathered and analyzed. Now, the data can be delivered easily and quickly through the LifeSource products, giving medical providers the vital data they need to make effective healthcare decisions.”

To earn the certification, AtTheScene was tested to be in accordance with applicable standards and certification criteria put forth by the Department of Health and Human Services (HHS). The approval designates that the software offers the functionality that enables eligible providers and hospitals to meet meaningful use requirements, qualifying these organizations to receive payments under the ongoing EHR adoption program.

LifeSource Health notes the following: The certification requirements are set by the Office of the National Coordinator for Health Information Technology (ONC-Health IT) 2015 Edition Health IT Module Certification. This Health IT Module is 2015 Edition compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services. An internet connection is required to use the platform. Additionally, a pre-defined connection with a health information exchange (HIE) and the platform is required. No clinical quality measures were tested.

About LifeSource Health, Inc.: LifeSource Health, Inc., is software solutions and health data access company that delivers vital digital patient data across the caregiver spectrum. Our premier product ‘AtTheScene’ provides essential health information to first responders quickly, accurately, and securely, when they need it most – at the scene. The company has offices in Syracuse, NY and Marietta, GA. Please visit lifesourcehealthinc.com for more information.

About Drummond Group LLC

Drummond Group LLC is a global software test and certification lab that serves a wide range of vertical industries. In healthcare, Drummond Group LLC tests and certifies Controlled Substance Ordering Systems (CSOS), Electronic Prescription of Controlled Substances (EPCS) software and processes, and Electronic Health Records (EHRs). Founded in 1999, and accredited for the Office of the National Coordinator Health IT Certification Program as an Authorized Certification Body (ACB) and an Authorized Test Lab (ATL), Drummond Group LLC continues to build upon its deep experience and expertise necessary to deliver reliable and cost-effective services. For more information, please visit http://www.drummondgroup.com.

Contact:

David LaVance, President
919-274-3010
David.LaVance@LifeSourceHealthInc.com

SOURCE: LifeSource Health, Inc.

ReleaseID: 457293